Jose Munoz-Olaya

Jose Munoz-Olaya is the Chief Scientific Officer of Valink Therapeutics, where he leads scientific strategy, multispecific ADC development, and all discovery and preclinical innovation across the company’s oncology portfolio. He joined Valink shortly after the company was established, serving as an external scientific advisor and helping to shape the transition from platform to therapeutics company; work he continued after being appointed CSO in 2024.

He brings more than 15 years of biotech and pharma leadership in multispecific antibodies, multifunctional protein therapeutics, and translational oncology, with a track record spanning discovery, platform strategy, early clinical development, multiple INDs, and one drug currently in Phase 1b.

Before joining Valink, Jose was at Takeda following its acquisition of Adaptate Biotherapeutics. At Takeda, he advanced multispecific antibody programmes from discovery toward clinical development, integrating Adaptate’s γδ T-cell engager technologies into the company’s wider pipeline. Prior to the acquisition, he served as Head of Preclinical at Adaptate, where he expanded the bispecific antibody and γδ T-cell biology platforms and led ADT-010, a novel γδ T-cell checkpoint modulator.

Earlier, he held roles at AstraZeneca, and spent eight years at F-star Therapeutics, where he led multispecific and immune-cell engager programmes from early discovery through pre-IND and Phase I, contributing to platform development, partnered assets, publications, and patents. His career began with an early role at Cambridge Antibody Technology, followed by a PhD and academic research period at the University of Barcelona.